From ‘Doc’s Opinion’, some more modern thinking regarding Cardio-Vascular issues.

” Epidemiological studies have shown that across cultures, cholesterol is linearly related to mortality from coronary artery disease (1).

However, when it comes to overall mortality, the issue is more complicated. Observational studies have shown a correlation between cholesterol levels and overall death rate in young and middle-aged people but not among the elderly (2,3). However, the mortality curve is J-shaped which means that those with the lowest cholesterol levels have increased mortality. ”

” These results may suggest that the efficacy of statins may be explained by other mechanisms than cholesterol lowering, such as reducing inflammation.  The cholesterol-independent or “pleiotropic” effects of statins include improving endothelial function, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress and inflammation, and inhibiting blood clotting mechanisms  ”

” GLAGOV is the first randomized placebo-controlled trial showing a positive effect on atherosclerotic plaque volume by adding a PCSK9-inhibitor on top of statin therapy in patients with coronary artery disease. Whether this transforms into clinical benefit remains to be seen. Despite these promising results our eyes must still be on long-term efficacy and safety concerns.

So, until more data is available, GLAGOV may reflect new hopes for the future but could also turn out to be nothing more than empty promises. ”

Another example of “unsettled science”, requiring greater attention.

Read the article here.